title: Prevention of rejection with BTI-322 after renal transplantation (results at 9 months).
authors.affiliation: Department of Renal and Pancreatic Transplantation, University of Louvain Medical School, Brussels, Belgium.
authors.forename: T
authors.initials: T
authors.lastname: Besse
authors.forename: J
authors.initials: J
authors.lastname: Malaise
authors.forename: M
authors.initials: M
authors.lastname: Mourad
authors.forename: Y
authors.initials: Y
authors.lastname: Pirson
authors.forename: J
authors.initials: J
authors.lastname: Hope
authors.forename: M
authors.initials: M
authors.lastname: Awwad
authors.forename: M
authors.initials: M
authors.lastname: White-Scharf
authors.forename: J P
authors.initials: JP
authors.lastname: Squifflet
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018801:CD2 Antigens / Q000276:immunology; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged
chemical_list: D000911:Antibodies, Monoclonal; D018801:CD2 Antigens; C105249:LO-CD2a